For metastatic GIST, which may not be amenable to surgery, a sequential approach using KIT/PDGFRA inhibitors followed by p53-targeted inhibitors or a combination of both from the outset could be considered [10]. Here, TP53 is linked to gastrointestinal stromal tumor.